Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Magnesium sulfate dried; Chloroform; Magnesium oxide light; Sodium hydroxide
The Boots Company Plc
A02AA04
Magnesium sulfate dried; Chloroform; Magnesium oxide light; Sodium hydroxide
47.5mg/1ml ; 3microlitre/1ml ; 52.5mg/1ml ; 15mg/1ml
Oral suspension
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 01060400
PRECAUTIONS BEFORE USE. DO NOT USE IF: - you have a serious digestive or stomach (gastro-intestinal) condition. - you have problems with your kidney or liver. - you are physically fragile or weak. AVOID USE during early pregnancy. IF YOU ARE TAKING ANY OTHER MEDICATION, PRESCRIBED OR OTHERWISE, TALK TO YOUR DOCTOR OR PHARMACIST BEFORE USE. The antacid properties of this product can reduce the effectiveness of some other medicines including some (but not all): - non-steroidal anti-inflammatory drugs (NSAIDs). - antibiotics or medicines used to treat infections. - epileptic therapy (phenytoin) - malaria treatment (chloroquine, hydroxychloroquine). - antipsychotic therapy (phenothiazines). - osteoperosis therapy (biphosphonates). - rheumatoid arthritis treatment (penicillamine). - preventative heart attack or stroke treatments. Store below 25°C. Do not freeze. Use within 1 month of opening. Do not use after the expiry date shown. DOSAGE, AS REQUIRED: Shake bottle before use. To be taken by mouth. 5ml = 1 teaspoon. revised date Dec ember 2015 Magnesium Hydroxide Mixture 8% w/w Oral suspension Magnesium Hydroxide Laxative for oral use for the relief of mild constipation KEEP OUT OF THE SIGHT AND REACH OF CHILDREN Marketing Authorisation Holder: Ayrton Saunders Ltd., 9 Arkwright Road, Astmoor Industrial Estate, Runcorn, Cheshire, WA7 1NU. Manufacturer: Pharmasol Ltd,. North Way, Andover, Hampshire, SP10 5AZ PL 16431/0174 Contains the active ingredient: magnesium oxide 275mg/5ml Other ingredients: levomenthol, sodium saccharin, phenoxyethanol, purified water. Adults (12 years +) & elderly: 25 - 50 ml (max daily dose 50ml) Children 6 - 12 years: 10 - 25 ml (max daily dose 25ml) Children 1 - 6 years: 5 - 10 ml (max daily dose 10ml) Not to be taken by children under 1 year old. Only use occasionally. If your symptoms do not improve, or in the event of an overdose, stop use and seek medical advice IMMEDIATELY. SIDE EFFECTS: This medicine can cause colic (waves of pain in the s t omach). Persistent over-use may result in hi Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Magnesium Hydroxide Mixture 8%w/w Oral suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Magnesium Hydroxide 8% w/w, equivalent to Magnesium Oxide 5.5% w/v. 3 PHARMACEUTICAL FORM Oral suspension 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For oral use for the relief of mild constipation 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For adults (including the elderly) 25 to 50ml orally as required (maximum daily dose 50ml) For children aged 6-12 years 10 to 25ml orally as required (maximum daily dose 25ml) For children aged 1-6 years 5 to 10ml orally as required (maximum daily dose 10ml) Not recommended for children under 1 year of age. Not recommended in cases of renal impairment of debilitation. 4.3 CONTRAINDICATIONS Should not be used where there are known or suspected acute gastro-intestinal conditions, or renal or hepatic impairment. 4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE Label warnings: Store below 25°C. Do not freeze. Shake well before use. Keep out of the sight and reach of children. Chronic use may result in hypermagnesia. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION The antacid properties of this preparation can lead to reduced absorption of diflusinal, azithromycin, ciprofloxacin, isoniazid, norfloxacin, ofloxacin, pivampicillin, rifampicin and most tetracyclines. Also reduces absorption of phenytoin, itraconazole, ketoconazole, fosinopril, chloroquine, hydroxychloroquine, phenothiazines, biphosphonates and penicillamine. The use of this product is not advised during dipyridamole therapy. The excretion of aspirin is increased and quinidine is decreased in alkaline urine which may occur with use of this product. 4.6 PREGNANCY AND LACTATION There is not or inadequate evidence of safety of use during pregnancy and lactation but has been used for many years without ill effect. As with all drugs, use during early pregnancy should be avoided. Can be used during late pregnancy and during lact Read the complete document